ARX three-lens brief
Evidence-based stock research on ARX. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA above 200-day MA (golden-cross regime); price above both. · Trading at 100% of its 52-week range — near the top of the band.
- Trading at 100% of its 52-week range — near the top of the band.
- 50-day MA above 200-day MA (golden-cross regime); price above both.
- Negative free cash flow last quarterly (-$1.48B).
- Reported earnings on 2026-11-12.
- Earnings in today (2026-11-12).
ARX closed at $19.87 (-0.20%) as of 2026-11-12. Market cap: $4.32B. Price is above the 50-day MA and above the 200-day MA. Positives: 50-day MA above 200-day MA (golden-cross regime); price above both.. Concerns: trading at 100% of its 52-week range — near the top of the band.; negative free cash flow last quarterly (-$1.48B).. Last quarter: Revenue $356.90M, net income $78.70M, free cash flow -$1.48B. Watching for: 2026-11-12 earnings release (today).
Why three lenses on ARX, not one.
A single reasoning model has blind spots it doesn’t know about. We examine ARX across Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://www.clearpathinvest.app/embed/ARX" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath ARX brief"></iframe>